This Article Full Text Full Text (PDF) CME: Take the course for this article: Gene-Expression Profiling and the Future of Adjuvant Therapy eLetters: Submit a response to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by van de Vijver, M. Search for Related Content PubMed PubMed Citation Articles by van de Vijver, M.

Gene-Expression Profiling and the Future of Adjuvant Therapy

Department of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands

Key Words. Gene-expression profiling • Prognostic tests • Predictive tests • Adjuvant • Neoadjuvant

Correspondence: Marc van de Vijver, M.D., Department of Pathology, Netherlands Cancer Institute, Plesmanlaan 121, 1066CX Amsterdam, The Netherlands. Telephone: 31-20-5122750; Fax: 31-20-5122759; e-mail: m.vd.vijver{at}nki.nl

Gene-expression profiling can help distinguish between patients at high risk and those at low risk for developing distant metastases, and so identify patients for adjuvant therapy. For several years, the Netherlands Cancer Institute has been working on gene-expression profiling of breast cancer using a microarray platform containing 25,000 genes. Using supervised classification, a prognostic classifier consisting of 70 genes could be identified. In addition to providing prognostic information, gene profiling should also enable us to detect patients who are likely to respond to particular adjuvant interventions. Well-known predictors for response to systemic therapy include estrogen receptor status HER-2 status, c-kit mutation, and epidermal growth factor receptor mutation. Because of the long periods required for predicting responsiveness in the adjuvant setting, neoadjuvant trials promise far quicker results. Several neoadjuvant studies are under way or planned to investigate gene-expression profiling as a means of predicting the therapeutic response to doce taxel (Taxotere^®; Aventis Pharmaceuticals Inc., Bridgewater, NJ, http://www.aventispharma-us.com), paclitaxel (Taxol^®; Bristol-Myers Squibb, Princeton, NJ, http://www.bms.com), cyclophosphamide, and doxorubicin (Adriamycin^®; Bedford Laboratories, Bedford, OH, http://www.bedfordlabs.com) in breast cancer patients. It is expected that in the coming years an increasing number of novel prognostic and predictive tests will help in guiding the adjuvant systemic treatment of breast cancer and other malignancies.

This article has been cited by other articles:

				Y. Sasaki, Y. Minamiya, N. Takahashi, T. Nakagawa, Y. Katayose, A. Ito, H. Saito, S. Motoyama, and J.-i. Ogawa REG1A Expression is an Independent Factor Predictive of Poor Prognosis in Patients with Breast Cancer Ann. Surg. Oncol., November 1, 2008; 15(11): 3244 - 3251. [Abstract] [Full Text] [PDF]

				M. Mimeault, P. P. Mehta, R. Hauke, and S. K. Batra Functions of Normal and Malignant Prostatic Stem/Progenitor Cells in Tissue Regeneration and Cancer Progression and Novel Targeting Therapies Endocr. Rev., April 1, 2008; 29(2): 234 - 252. [Abstract] [Full Text] [PDF]

				L. Pusztai Current Status of Prognostic Profiling in Breast Cancer Oncologist, April 1, 2008; 13(4): 350 - 360. [Abstract] [Full Text] [PDF]

				M. Mimeault, S. L. Johansson, G. Vankatraman, E. Moore, J.-P. Henichart, P. Depreux, M.-F. Lin, and S. K. Batra Combined targeting of epidermal growth factor receptor and hedgehog signaling by gefitinib and cyclopamine cooperatively improves the cytotoxic effects of docetaxel on metastatic prostate cancer cells Mol. Cancer Ther., March 1, 2007; 6(3): 967 - 978. [Abstract] [Full Text] [PDF]

				N. Wolmark Provocative Optimism in the Treatment of Early Stage Disease Oncologist, October 1, 2005; 10(suppl_2): 1 - 3. [Full Text] [PDF]